Liverpool Care Pathway for the Dying Patient (LCP)

National LCP Renal Steering Group

Guidelines for LCP Drug Prescribing in Advanced Chronic Kidney Disease (estimated glomerular filtration rate < 30 ml/min)

June 2008
**Policy**
- Estates
- Commissioning
- IM & T
- Finance
- Social Care / Partnership Working

**Document Purpose**
Best Practice Guidance

**Gateway Reference**
8611

**Title**
Guidelines for LCP Prescribing in Advanced Chronic Kidney Disease

**Author**
DH Renal NSF Team and Marie Curie Palliative Care Institute

**Publication Date**
01 May 2008

**Target Audience**
GPs, Renal Clinical Directors, British Renal Society Council Members, Renal Pharmacy Group Members, Renal Nursing Group Members, Pharmacist, Specialist Palliative Care Teams, End of Life Care Leads, staff in Renal Units.

**Circulation List**

**Description**
Letter on Renal End of Life Care enclosing link to Prescribing Guidelines

**Cross Ref**
National Service Framework for Renal Services Part 2

**Superseded Docs**
n/a

**Action Required**
To note and consider best practice

**Timing**
n/a

**Contact Details**
Jane Heaton  
Renal and Vascular Policy Manager  
Department of Health  
Room 403 Wellington House  
133-155 Waterloo Road  
London SE1 8UG  
tel 020 7972 1047  
www.dh.gov.uk/renal

**For Recipient's Use**
Foreword

Recent advances in the treatment of renal failure have meant that many patients are now surviving for longer, and with increased quality of life, due to renal replacement therapies and kidney transplants. Over 50% of the best-matched kidney transplants are still functioning after twenty-five years and some patients can survive for over twenty years on dialysis. But for those patients in whom such interventions are not appropriate or no longer effective, the shift to palliative care should be encouraged to maintain a good quality of life in dying patients.

In 2005 a National LCP Renal Steering Group was developed and utilised an action research approach that has been used to facilitate the transferability of the LCP for use in these more specialist renal areas. This excellent programme included the design of patient and carers information, professional guidance and this innovative and much needed drug guidance for patients with advanced and chronic kidney disease in the last days of life.

This guidance will be welcomed by all specialists and generalists working to ensure models of best practice in the last days of life. The authors have provided clear guidance and advice on medicines management and the control of distressing symptoms. It will enable the service to respond to and respect the wishes of patients and their carers.

All patients with advanced chronic kidney disease deserve optimum care in the last days of life. I believe the LCP and this associated guidance provides us with a significant step towards providing a model of excellence.

Dr Donal O'Donoghue
National Clinical Director for Kidney Care, Department of Health

Contents

<table>
<thead>
<tr>
<th>Introduction</th>
<th>Page 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Guidelines</td>
<td>Page 5</td>
</tr>
<tr>
<td>Opioid Conversion Table</td>
<td>Page 6</td>
</tr>
<tr>
<td>Terminal restlessness and agitation Guidelines</td>
<td>Page 7</td>
</tr>
<tr>
<td>Respiratory tract secretions Guidelines</td>
<td>Page 8</td>
</tr>
<tr>
<td>Nausea and Vomiting Guidelines</td>
<td>Page 9</td>
</tr>
<tr>
<td>Dyspnoea Guidelines</td>
<td>Page 10</td>
</tr>
<tr>
<td>Project Group</td>
<td>Page 11-12</td>
</tr>
<tr>
<td>Bibliography</td>
<td>Page 13</td>
</tr>
<tr>
<td>Contact Details</td>
<td>Page 14</td>
</tr>
</tbody>
</table>
Introduction

It is recognised that most patients with kidney disease do not die directly from kidney failure, but from other medical problems. However renal impairment, even if not the primary problem, is an important consideration when considering prescribing drugs in these patients. This is particularly the case for opioids, as metabolites can and do accumulate in renal impairment and may lead to significant toxicity if this is not recognised. These guidelines are designed to optimise the risk/benefit ratio of these drugs. However, it is important to be aware that the risks of toxicity and side effects increase cumulatively as GFR falls. These guidelines are aimed at controlling symptoms once it is recognised that the patient is dying and in the last few days of life. Usually at this stage, the patient will require medication to be given by the subcutaneous route.

Prescribing in Advanced Chronic Kidney Disease

The evidence for symptom control in the dying patient is limited and therefore all of the guidelines are based on level 3 and 4 evidence and expert opinion (DoH 2005).

In general, most medications are not excreted well in advanced Chronic Kidney Disease (CKD). It is therefore important to choose medication least likely to accumulate and cause adverse effects. Drug doses may require reduction and dosing intervals may need to be increased to reduce drug toxicity.

Once administered, a drug may have a longer duration of effect than expected and therefore PRN or regular doses of drugs may need to be given less often.

With regard to management of pain and dyspnoea, the evidence for the use of opioids in renal failure is limited. However, these guidelines aim to provide symptom control safely and without development of opioid toxicity. It is very important to titrate the medication carefully and frequently review the patient as considerable variation between patients can exist.

These guidelines were produced by the National LCP Renal Steering Group based on level 3 and 4 evidence and expert opinion. If you would like to refer to this in your clinical practice may we suggest that you liaise with your local drugs & therapeutics – pharmacy policy & procedure, which will determine safe practice & prescribing protocols within your clinical area.

We also suggest that liaison between the Hospital Specialist Palliative Care Team, End of Life Care Leads & Conservative Management Renal Leads is key in caring for patients with advanced CKD in the last hours & days of life.

Professor John Ellershaw
Director – Marie Curie Palliative Care
Institute Liverpool
National Clinical Lead Palliative Care – (Specialist)

Dr Claire Douglas
SpR in Palliative Medicine
Chair – Expert Consensus Group
Pain

Patient is in pain

Is patient already taking oral opioids

Yes

1. If patient is already taking strong opioids, Contact the Specialist Palliative Care Team for Advice, if they are not available then please see conversion chart on page 5

NO

1. Fentanyl 25 micrograms S/C prn
   If fentanyl is temporarily unavailable *

2. If three of more doses are required over 24 hours consider starting a S/C Syringe Driver of Fentanyl or Alfentanil
3. Fentanyl 100-250 micrograms in a syringe driver over 24hrs, prn dose should be 1/8th of the 24 hr dose
   EXAMPLE:
   100 micrograms/24hrs give 12.5 micrograms prn, for 200 micrograms /24hrs give 25 micrograms prn

Patient’s pain is controlled

Is patient already taking oral opioids

YES

1. Fentanyl 25 micrograms S/C prn
   If fentanyl is temporarily unavailable *

NO

1. Fentanyl 25 micrograms S/C prn
   If fentanyl is temporarily unavailable *

2. If three of more doses are required over 24 hours consider starting a S/C Syringe Driver of Fentanyl or Alfentanil
3. Fentanyl 100-250 micrograms in a syringe driver over 24hrs, prn dose should be 1/8th of the 24 hr dose
   EXAMPLE:
   100 micrograms/24hrs give 12.5 micrograms prn, for 200 micrograms /24hrs give 25 micrograms prn

SUPPORTIVE INFORMATION:

- To convert from other strong opioids contact Specialist Palliative Care Team / Pharmacy for further advice & support as needed

- If Fentanyl is temporarily unavailable give:
  Oxycodone 1-2 milligrams S/C prn
  or
  Morphine 1.25 – 2.5 milligrams S/C PRN

- Many of the opioid analgesics and their metabolites may accumulate in Renal Failure causing toxicity with myoclonic jerks, profound narcosis and respiratory depression. Morphine and its metabolites are most likely to cause toxicity. Fentanyl and Alfentanil are less likely to cause these problems, as the metabolites are not active. The duration of effect from Morphine and Oxycodone may last longer than in a patient with normal renal function. (See conversion table on Page 5)

- If Fentanyl dose exceeds 500 micrograms in a Syringe Driver seek expert advice for conversion to Alfentanil

- If symptoms persist contact the Specialist Palliative Care Team

- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs

- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base
### OPIOID CONVERSION TABLE

Opioid equivalent doses (Note: There is no exact equivalence between opioids therefore starting low and titrating upwards is recommended safe practice)

<table>
<thead>
<tr>
<th>ORAL MORPHINE</th>
<th>DIAMORPHINE INJECTION</th>
<th>MORPHINE INJECTION</th>
<th>FENTANYL INJECTION</th>
<th>ALFENTANIL INJECTION</th>
<th>OXYCODONE INJECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 milligrams orally</td>
<td>1.25 milligrams subcutaneously</td>
<td>2 milligrams subcutaneously</td>
<td>25 micrograms subcutaneously</td>
<td>125 micrograms subcutaneously</td>
<td>1 milligram subcutaneously</td>
</tr>
<tr>
<td>8 milligrams orally</td>
<td>2.5 milligrams subcutaneously</td>
<td>4 milligrams subcutaneously</td>
<td>50 micrograms subcutaneously</td>
<td>250 micrograms subcutaneously</td>
<td>2 milligrams subcutaneously</td>
</tr>
</tbody>
</table>

Note: alfentanil is not ideal for prn use since it has a very short half life, and doses may only last 1-2 hours

Note: Do not use these equivalent doses for larger doses without specialist palliative advice, as the small numbers entailed have been rounded up.

### Approximately equivalent opioid doses for starting doses in continuous subcutaneous infusions

(Starting doses should be based on prior opioid requirements, and titrated upwards according to the amount of subsequent PRN doses required in addition to the continuous infusion – there is no upper limit provided the pain is responding well to the opioid, and there are no symptoms or signs of adverse effects or toxicity. Most patients with renal failure require only low doses – if the dose is escalating, advice should be sought from the Palliative Care team)

<table>
<thead>
<tr>
<th>DIAMORPHINE INJECTION</th>
<th>MORPHINE INJECTION</th>
<th>FENTANYL INJECTION</th>
<th>ALFENTANIL INJECTION</th>
<th>OXYCODONE INJECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 - 10 milligrams</td>
<td>8 - 16 milligrams</td>
<td>100 – 200 micrograms</td>
<td>500 micrograms - 1 milligram</td>
<td>4 – 8 milligrams</td>
</tr>
</tbody>
</table>

Do not use diamorphine in continuous infusion because of the high risk of accumulation and adverse effects

Do not use morphine in continuous infusion because of the high risk of accumulation and adverse effects
Terminal restlessness and agitation

Present

1. MIDAZOLAM 2.5 milligrams S/C prn

2. Review the required medication after 24hrs, if three or more prn doses have been required then consider a S/C syringe driver over 24 hrs (Midazolam 5 –10 micrograms S/C) over 24 hrs in a Syringe Driver.

3. Continue to give prn dosage accordingly

Absent

1. MIDAZOLAM 2.5 milligrams S/C prn

SUPPORTIVE INFORMATION:

- If symptoms persist contact the Specialist Palliative Care Team
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base
**Respiratory tract secretions**

**Present**

1. Glycopyrronium 200 micrograms (0.2 milligrams) S/C prn

2. Continue to give S/C prn dosage accordingly

3. If three or more doses of prn Glycopyrronium are required then consider a S/C syringe driver with 600 – 1800 micrograms (0.6 – 1.8 milligrams) S/C over 24hrs

**Absent**

1. Glycopyrronium 200 micrograms (0.2 milligrams) S/C prn

**SUPPORTIVE INFORMATION:**

- If symptoms persist contact the Specialist Palliative Care Team
- Hyoscine butylbromide 20 milligrams s/c prn may be used as an alternative. (If a S/C Syringe Driver is required then consider Hyoscine butylbromide 40 – 120 milligrams over 24 hours)
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- *The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base*

  Hyoscine Hydrobromide is not usually recommended
Nausea and Vomiting

Present

Haloperidol 0.5 – 1.5 milligrams S/C prn

Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.

SUPPORTIVE INFORMATION:

- If symptoms persist contact the Specialist Palliative Care Team
- Levomepromazine 6.25 milligrams S/C prn – suitable alternative second line (if a Syringe Driver is required then consider 6.25 milligrams S/C in a Syringe Driver over 24 hours)
- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs.
- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base

Cyclizine is not usually recommended

Absent

Haloperidol 0.5 – 1.5 milligrams S/C prn

Review the required medication after 24hrs, if three or more prn doses have been required then consider Haloperidol 1.5 – 3 milligrams in a S/C syringe driver over 24 hrs
Dyspnoea

Present

Is patient already taking oral opioids for breathlessness

Yes

Fentanyl 25 micrograms S/C prn

If symptoms persist contact the Specialist Palliative Care Team

2. If three of more doses are required over 24 hours consider starting a S/C Syringe Driver of Fentanyl or Alfentanil
3. Fentanyl 100-250 micrograms in a syringe driver over 24hrs, prn dose should be 1/8th of the 24 hr dose
EXAMPLE:
100 micrograms/24hrs give 12.5 micrograms prn, for 200 micrograms /24hrs give 25 micrograms prn

No

If fentanyl is temporarily unavailable *

Fentanyl 25 micrograms S/C prn

If fentanyl is unavailable:
Morphine 1.25 – 2.5 milligrams S/C prn
Or
Oxycodone 1-2 milligrams S/C prn

Absent

Supportive Information:

- If symptoms persist contact the Specialist Palliative Care Team
- To convert from other strong opioids contact Specialist Palliative Care Team / Pharmacy for further advice & support
- If the patient is breathless and anxious consider Midazolam 2.5 milligrams S/C prn
- * If Fentanyl is temporarily unavailable give:
  
  Oxycodone 1-2 milligrams S/C prn or
  Morphine 1.25 – 2.5 milligrams S/C PRN

- Many of the opioid analgesics and their metabolites may accumulate in Renal Failure causing toxicity with myoclonic jerks, profound narcosis and respiratory depression. Morphine and its metabolites are most likely to cause toxicity. Fentanyl and Alfentanil are less likely to cause these problems, as the metabolites are not active. The duration of effect from Morphine and Oxycodone may last longer than in a patient with normal renal function. (See conversion table on Page 5)

- Anticipatory prescribing in this manner will ensure that in the last hours / days of life there is no delay responding to a symptom if it occurs

- The LCP National Renal Steering Group produced these guidelines according to best practice and evidence base
These guidelines have been produced by the National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group building on recent work undertaken by the Merseyside & Cheshire Palliative Care Network Audit Group.

This work has been led by:

**Dr Claire Douglas**, Specialist Registrar in Palliative Medicine at Mersey Deanery

Supported by:
- Merseyside & Cheshire Palliative Care Network Audit Group – Renal Audit
- National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group

**Expert Consensus Group**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Claire A Douglas</td>
<td>SpR in Palliative Medicine</td>
</tr>
<tr>
<td>Dr Stephanie Gomm</td>
<td>Consultant in Palliative Medicine</td>
</tr>
<tr>
<td>Dr Jo Chambers</td>
<td>Consultant in Palliative Medicine</td>
</tr>
<tr>
<td>Dr Matthew Howse</td>
<td>Consultant Nephrologist</td>
</tr>
<tr>
<td>Dr Polly Edmonds</td>
<td>Consultant in Palliative Medicine</td>
</tr>
<tr>
<td>Dr Fliss Murtagh</td>
<td>SpR Research Training Fellow</td>
</tr>
<tr>
<td>Dr Alistair Chesser</td>
<td>Consultant Nephrologist</td>
</tr>
<tr>
<td>Dr Martine Meyer</td>
<td>Consultant in Palliative Medicine</td>
</tr>
</tbody>
</table>

**National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group**

![Table of names and titles related to the National Liverpool Care Pathway for the Dying Patient (LCP) Renal Steering Group.](https://example.com/table.png)

© National LCP Renal Steering Group
<table>
<thead>
<tr>
<th>Salford Royal Foundation NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Stephanie Gomm</td>
</tr>
<tr>
<td>Bernadette Wilcox</td>
</tr>
<tr>
<td>Dr David New</td>
</tr>
<tr>
<td>Cath Byrne</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Royal Liverpool &amp; Broadgreen University Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Matthew Howse</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wirral Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Cathy Lewis-Jones</td>
</tr>
<tr>
<td>Sandra Rowlands</td>
</tr>
<tr>
<td>Sheila Nugent</td>
</tr>
<tr>
<td>Hayley Lloyd</td>
</tr>
<tr>
<td>Sue Peters</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Kings College Hospital NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Polly Edmonds</td>
</tr>
<tr>
<td>Dr Fliss Murtagh</td>
</tr>
<tr>
<td>Mary Preston</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Portsmouth Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kay McConville</td>
</tr>
<tr>
<td>Angela Devonport</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wolverhampton NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pam Magee</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Barts and the London NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Alistair Chesser</td>
</tr>
<tr>
<td>Teresa Coyne</td>
</tr>
<tr>
<td>Pat Langstone</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Epsom &amp; St Helier Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Martine Meyer</td>
</tr>
<tr>
<td>Valerie Crooks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>National Kidney Federation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Statham</td>
</tr>
<tr>
<td>Robert Dunn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dudley Group of Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Ruth Benzmira</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Department of Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sue Hawkett OBE</td>
</tr>
<tr>
<td>Claire Henry</td>
</tr>
<tr>
<td>Jane Verity</td>
</tr>
<tr>
<td>Gerry Lynch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brighton &amp; Sussex Hospitals NHS Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Andreas Hiersche</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>St Catherine’s Hospice, Scarborough</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Miriam Johnson</td>
</tr>
</tbody>
</table>
BIBLIOGRAPHY


CONTACT DETAILS

Should you wish to contact the Marie Curie Palliative Care Institute Liverpool, then please see the contact details below

Professor John Ellershaw
Director
Marie Curie Palliative Care Institute Liverpool
c/o Marie Curie Hospice Liverpool
Speke Road,
Woolton
Liverpool
L25 8QA

T: 0151 801 1490
E: john.ellershaw@mariecurie.org.uk

Deborah Murphy
Associate Director
Marie Curie Palliative Care Institute Liverpool
c/o Directorate of Specialist Palliative Care
1st Floor, Linda McCartney Centre
The Royal Liverpool and Broadgreen University Hospitals
Prescot Street
Liverpool
L7 8XP

T: 0151 706 2274
E: deborah.murphy@rlbuht.nhs.uk

USEFUL WEBSITES

Marie Curie Palliative Care Institute Liverpool www.mcpcil.org.uk
Department of Health www.dh.gov.uk
The Renal Association www.renal.org
British Renal Society www.britishrenal.org
End of Life Care Programme www.endoflifecare.nhs.uk